Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q54719175)
Watch
English
Skin toxicities of targeted therapies.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
title
Skin toxicities of targeted therapies.
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
author name string
Siegfried Segaert
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
Gabriela Chiritescu
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
Liesbeth Lemmens
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
Kristien Dumon
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
Eric Van Cutsem
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
Sabine Tejpar
series ordinal
6
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
publication date
1 September 2009
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
published in
European Journal of Cancer
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
volume
45 Suppl 1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
page(s)
295-308
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
cites work
Targeting the EGFR pathway for cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanisms of cutaneous toxicities to EGFR inhibitors.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous side-effects of kinase inhibitors and blocking antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nail toxicity associated with epidermal growth factor receptor inhibitor therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Epidermal growth factor receptor inhibition induces trichomegaly.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Eye complications of cetuximab therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
[Clinical appearance and management of cutaneous side effects of EGF receptor inhibitors]
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous side effects of EGF-receptor inhibition and their management
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cetuximab for the treatment of colorectal cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapeutic agents and the skin: An update
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970044-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0959-8049(09)70044-9
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
PubMed publication ID
19775626
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19775626
retrieved
3 June 2018
reference URL
http://europepmc.org/abstract/MED/19775626
ResearchGate publication ID
51438454
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit